TickerFacts.

Upstream Bio, Inc. (UPB): R&D Expense

Annual figures by period end, from SEC filings.

$136.81M
Year ended 2025-12-31
$145.80M
Trailing 12 months to 2026-06-30
2023-12-31: $31.80M2024-12-31: $62.97M2025-12-31: $136.81M$136.81M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$136.81M+117.3%2026-03-26, From 2025-01-01
2024-12-31$62.97M+98.0%2026-03-26, From 2024-01-01
2023-12-31$31.80Mn/a2025-03-12, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Upstream Bio, Inc. (UPB)2025-12-31$136.81M+117.3%
Cartesian Therapeutics, Inc. (RNAC)2025-12-31$58.03M+28.7%
Xenetic Biosciences, Inc. (XBIO)2025-12-31$3.07M-6.8%
GeoVax Labs, Inc. (GOVX)2025-12-31$18.12M-23.6%
Camp4 Therapeutics Corp (CAMP)2025-12-31$38.20M-1.6%
Marker Therapeutics, Inc. (MRKR)2025-12-31$11.80M-12.4%
Korsana Biosciences, Inc. (KRSA)2025-12-31$959.0K+235.3%
Dianthus Therapeutics, Inc. (DNTH)2025-12-31$145.64M+75.2%
CervoMed Inc. (CRVO)2025-12-31$21.82M+16.1%

Compare UPB, RNAC, XBIO, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗